Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.01 USD

32.01
1,959,949

+0.44 (1.39%)

Updated May 31, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study

by Zacks Equity Research

Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

by Zacks Equity Research

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.

Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.

Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Sarepta (SRPT) Sells Priority Review Voucher for $102M

by Zacks Equity Research

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug

by Zacks Equity Research

Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.

FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing

by Zacks Equity Research

A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Roche (RHHBY) Gets FDA Approval for Blood Cancer Drug Columvi

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Novartis (NVS) to Buy Chinook for $3.5B to Strengthen Pipeline

by Zacks Equity Research

Novartis (NVS) is looking to strengthen its renal pipeline with the acquisition of Chinook Therapeutics for $3.5 billion, which adds two late-stage medicines in development for rare, severe chronic kidney diseases.

Roche (RHHBY) Announces Positive Results From PNH Studies

by Zacks Equity Research

Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

by Zacks Equity Research

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

by Zacks Equity Research

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

by Zacks Equity Research

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal

by Zacks Equity Research

At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.

Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

by Zacks Equity Research

Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

by Zacks Equity Research

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

Kinjel Shah headshot

5 Large Drug Stocks to Watch From a Thriving Industry

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

by Zacks Equity Research

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

by Zacks Equity Research

The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

by Zacks Equity Research

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.